Biotechnology company Can-Fite BioPharma Ltd (NYSE American:CANF) (TASE:CFBI) disclosed on Friday that its net loss was USD7.84m for the nine months ended 30 September 2019.
This reflects a dip in earnings when compared with a lower net loss of USD3.14m for the same period in 2018.
Revenues of USD1.84m were generated for the nine months ended 30 September 2019, down from revenues of USD3.53m for the same period of 2018, mainly due to the recognition of advance payment under the distribution agreement with CMS Medical.
Research and development (R&D) expenses of USD7.01m were recorded for the nine months ended 30 September 2019, a rise over R&D of USD4.05m for the same period of 2018.
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025